$CGC

Yanofsky Theresa sold $14K of CGC

Yanofsky Theresa sold 15,054 shares of Canopy Growth Corp (CGC) at $0.92 on 2026-06-26.

Original reporting
SEC EDGAR · Yanofsky Theresa
Published Jun 29, 2026, 8:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 29, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CGC
Neutral
medium confidence
Mentioned
$CGC
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CGCNeutralLow
01

Why it matters

The newest fact is the reported open-market sale size, price, and post-transaction holdings; it does not include any company performance or guidance update.

02

Market read

Traders may note insider selling, but the disclosure alone is unlikely to drive a durable repricing without additional catalysts.

03

What to watch

Insider sales often occur for non-informational reasons; without follow-on filings (buys, multiple sales, or changes in control), signal quality is low.

Relevance 3/10Novelty 3/10Timing: SEC Form 4 filed 2026-06-29 (covers sale dated 2026-06-26)

Background

The article is an SEC Form 4 insider transaction disclosure for Canopy Growth Corp (CGC).

Company-level read

Ticker impact

$CGCNeutralMedium confidence
Context

Canopy Growth director Yanofsky sold 15,054 shares in an open-market transaction at $0.9237 on 2026-06-26, per Form 4.

Expected impact

Low near-term impact; any reaction is likely muted unless part of a larger pattern.

Evidence & confidence

The filing is a Form 4 open-market sale with no 10b5-1 plan stated, but the article provides no new operational/regulatory catalyst or guidance change.

Market effects

No sector read-through; this is a single-insider transaction with no disclosed company event.

None indicated.

None indicated.

Counterpoint

Absence of a stated 10b5-1 plan could be interpreted as discretionary selling, but the article lacks context (taxes, diversification, liquidity needs).

Key entities

  • Canopy Growth Corp

    Subject of the Form 4 insider sale disclosure.

  • Yanofsky Theresa

    Director who sold 15,054 shares at $0.9237/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CURLFHighAI 9/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf has made an unsolicited bid for Aurora Cannabis, offering a 45% premium. Aurora has not accepted the deal. Tilray Brands and Canopy Growth are also engaging in consolidation. Aurora recently acquired Safari Flower, while Canopy bought MTL Cannabis. Tilray is diversifying into alcohol and CBD. Investors should consider risks of consolidation strategies.

$CURLFHighAI 8/10

Curaleaf's Hostile Takeover Bid for Aurora Is Just the Tip of the Iceberg for Cannabis Consolidation. These 2 Stocks Could Be the Biggest Winners.

Curaleaf (CURLF) has made an unsolicited bid for Aurora Cannabis (ACB), offering a 45% premium. Aurora's response was noncommittal. Canopy Growth (CGC) and Tilray Brands (TLRY) are also consolidating, with Tilray expanding into alcohol and CBD. Investors may benefit from acquisitions, but risks include integration challenges and leverage.

$CGCMedAI 8/10

Cannabis Operator CGC Rises 15% in a Month: Time to Buy, Hold or Sell?

Canopy Growth Corporation (CGC) shares rose 15% in a month after reporting Q1 fiscal 2027 earnings that beat estimates, showing revenue growth and improved margins. The company's cannabis business is improving, with increased revenues and narrowing losses. However, cash flow remains a concern, and competition in the cannabis market is stiff. Analysts have slightly improved loss estimates but maintain a 'Hold' rating.

$CURLFMedAI 8/10

Curaleaf Wants to Buy Aurora Cannabis for $272 Million. Is Canopy Growth the Next Marijuana Takeover Target?

Curaleaf launched an unsolicited offer to buy Aurora Cannabis for $272 million, or $4 per share, about a 45% premium to Aurora’s 30-day VWAP, aiming for about $1.5 billion revenue, $350 million adjusted EBITDA, and $40 million annual cost synergies. The article also discusses whether Canopy Growth could be a future acquisition target, citing its turnaround and global medical cannabis platform.